Lakefront board member Fontoura resigns after Sanofi names him R&D chief

Lakefront Biotherapeutics NV announced on July 13, 2026 that Dr. Paulo Fontoura has tendered his resignation from the Board of Directors following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA.¹

Board Chair Gino Santini commented on the departure, saying he wanted to congratulate Fontoura on the assignment and thank him for his insight and guidance during his tenure on the board, adding that the company expects to appoint a successor at the earliest practical opportunity.¹

The company described itself in the release. Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company focused on building a pipeline of medicines for serious diseases with high unmet need, and has established a clinical-stage portfolio in immunology and inflammation anchored by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases.¹

In its forward-looking statements section, the filing noted specific risks tied to this transition. These include the risk that Lakefront will encounter challenges appointing or retaining a new director and that it may not be able to realize the expected benefits from the appointment of a new director.¹

The release was filed as an exhibit to a Form 6-K report submitted to the SEC, and Lakefront indicated it files annual reports under Form 20-F rather than Form 40-F.¹ No timeline for naming Fontoura's successor was specified beyond the board chair's stated intent to act "at the earliest practical opportunity."